Achilles Therapeutics Shares Are Trading Higher: What You Need To Know
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 19 2024
0mins
Source: Benzinga
Strategic Shift: Achilles Therapeutics is discontinuing its TIL-based cNeT program and Phase I/IIa trials to focus on collaborations for alternative cancer treatment modalities, such as neoantigen vaccines and TCR-T therapies.
Financial Advisory and Workforce Reduction: The company has engaged BofA Securities to explore potential acquisitions or asset sales while implementing cost-cutting measures, including a proposed workforce reduction, although it will retain essential staff during the review process.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
